Related Experiment Videos
Myelography with metrizamide in children.
1Department of Radiology, University Hospital, Oslo, Norway.
Acta Radiologica. Supplementum
|January 1, 1977
Summary
Metrizamide (Amipaque) myelography in children showed few adverse effects, even with higher doses relative to body weight. This study supports its use in pediatric neuroimaging.
Area of Science:
- Neuroradiology
- Pediatric Imaging
- Contrast Media
Background:
- Metrizamide (Amipaque) is a non-ionic water-soluble contrast agent.
- Myelography is an imaging technique used to visualize the spinal canal.
Purpose of the Study:
- To evaluate the safety and efficacy of metrizamide (Amipaque) for pediatric myelography.
- To determine appropriate dosing and concentrations for children.
Main Methods:
- Thirty myelographies were performed on 25 pediatric patients.
- Metrizamide (Amipaque) contrast medium was administered at concentrations of 170 to 250 mg I/ml.
- Doses were adjusted based on body weight and brain weight comparisons.
Main Results:
- The procedure resulted in only a few minor adverse effects.
- Pediatric doses were higher than adult doses relative to body weight.
- Concentrations used ranged from 170 to 250 mg I/ml.
Conclusions:
- Metrizamide (Amipaque) myelography is generally safe for pediatric use.
- The contrast agent is well-tolerated in children, with minimal side effects observed.
- This study provides evidence for the safe application of metrizamide in pediatric neuroimaging.